Methods of inhibiting poxvirus growth
AssigneeThe Salk Institute for Biological Studies
InventorsBartholomew M. Sefton, Roberta J. Schulte
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Salk Institute for Biological Studies
InventorsBartholomew M. Sefton, Roberta J. Schulte
Estimating the term…
This disclosure ascribes new functions to derivatives of tetralin, anthraquinone, naphthylamine, tri-amino-pyrimidine, xanthen-3-one, and/or cinnamic acid (including, for example, NSC270718R, NSC117285R, NSC170008Y, NSC306711P, NSC119913X, NSC119915Z, NSC119911V, NSC119910U, NSC128437O, NSC125908P, NSC9600Q, or NSC13778J, each obtained from the Structure Diversity Set, National Institutes of Health, National Cancer Institute, Developmental Therapeutics Program). These compounds are shown to be effective inhibitors of viral essential protein kinases (such as poxvirus B1 and/or F10 protein kinases). Exemplary chemical structures for viral protein kinase (VPK) inhibitors are provided, as are methods of using such compounds, for instance, to inhibit VPK activity and/or poxvirus growth, and/or for the treatment of poxvirus infection. Also provided are pharmaceutical compositions including disclosed VPK inhibitors.
A method of inhibiting a poxviral protein kinase comprising contacting the poxviral protein kinase with an inhibitory amount of at least one compound having the formula:
A method of inhibiting poxvirus growth comprising contacting the poxvirus with a growth inhibitory amount of at least one compound having the formula:
A method for treating poxvirus infection in a subject, comprising administering to a subject a therapeutically effective amount of at least one compound having the formula:
Dependencies are inferred from the claim text.